⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14565314 | 1.00 | — | — | |
| SCHEMBL12450451 | 1.00 | — | — | |
| SCHEMBL22461541 | 0.88 | — | — | |
| SCHEMBL15445060 | 0.81 | STAT3 (0.33) | — | |
| SCHEMBL26073708 | 0.77 | — | — | |
| SCHEMBL12450450 | 0.75 | TSHR (0.51) | — | |
| SCHEMBL11949492 | 0.75 | TSHR (0.51) | — | |
| SCHEMBL23383846 | 0.72 | STAT3 (0.39) | — | |
| SCHEMBL18973582 | 0.72 | — | — | |
| SCHEMBL10420507 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024013334-A1 | NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF AGT IN A CELL | SILENCE THERAPEUTICS GMBH (DE) | 2024-01-18 | — | — | WO | disclosed |
| US-11820971-B2 | Nucleic acids for inhibiting expression of PROS1 in a cell | Universität Bern (CH) | 2023-11-21 | — | — | US | disclosed |
| US-11820971-B2 | Nucleic acids for inhibiting expression of PROS1 in a cell | Universität Bern (CH) | 2023-11-21 | — | — | US | disclosed |
| US-20230265438-A1 | NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF CNNM4 IN A CELL | ASOCIACION CENTRO DE INVESTIG COOPERATIVA EN BIOCIENCIAS CIC BIOGUNE (ES) | 2023-08-24 | — | — | US | disclosed |
| US-20230265438-A1 | NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF CNNM4 IN A CELL | ASOCIACION CENTRO DE INVESTIG COOPERATIVA EN BIOCIENCIAS CIC BIOGUNE (ES) | 2023-08-24 | — | — | US | disclosed |
| WO-2023152286-A1 | NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF MASP-2 IN A CELL | SILENCE THERAPEUTICS GMBH (DE) | 2023-08-17 | — | — | WO | disclosed |
| WO-2023031359-A1 | NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF COMPLEMENT FACTOR B (CFB) IN A CELL | SILENCE THERAPEUTICS GMBH (DE) | 2023-03-09 | — | — | WO | disclosed |
| US-20230019513-A1 | NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF PROS1 IN A CELL | Universität Bern (CH) | 2023-01-19 | — | — | US | disclosed |
| WO-2022096424-A1 | NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF PROS1 IN A CELL | Universität Bern (CH) | 2022-05-12 | — | — | WO | disclosed |
| WO-2021239825-A1 | NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF CNNM4 IN A CELL | SILENCE THERAPEUTICS GMBH (DE) | 2021-12-02 | — | — | WO | disclosed |
| WO-2020225301-A1 | NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF PROS1 IN A CELL | Universität Bern (CH) | 2020-11-12 | — | — | WO | disclosed |
| WO-2019193144-A1 | siRNAs WITH VINYLPHOSPHONATE AT THE 5' END OF THE ANTISENSE STRAND | SILENCE THERAPEUTICS GMBH (DE) | 2019-10-10 | — | — | WO | disclosed |
| WO-2019193189-A1 | siRNAs WITH AT LEAST TWO LIGANDS AT DIFFERENT ENDS | SILENCE THERAPEUTICS GMBH (DE) | 2019-10-10 | — | — | WO | disclosed |